SCHEMBL418948

SCHEMBL418948

CC1(C)C2CC[C@]3(C)[C@H](C(=O)C[C@@H]4[C@H]5C[C@@](C)(C(=O)NO)CC[C@]5(C)CC[C@]43C)[C@@]2(C)CC[C@@H]1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 6/20 0.57
HSD11B2 P80365 5/20 0.57
EGLN2 Q96KS0 3/20 0.45
EGLN1 Q9GZT9 3/20 0.45
EGLN3 Q9H6Z9 3/20 0.45
P4HTM Q9NXG6 3/20 0.45
CES2 O00748 4/20 0.45
CES1 P23141 4/20 0.45
PTPN1 P18031 4/20 0.44
CYP3A4 P08684 2/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
AKR1B10 O60218 1/20 0.44
LMNA P02545 1/20 0.44
ALOX5 P09917 1/20 0.44
PRKCH P24723 1/20 0.44
PTPN6 P29350 1/20 0.44
KMT2A Q03164 1/20 0.44
PTPN11 Q06124 1/20 0.44
SLCO1B3 Q9NPD5 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL418949 0.90 HSD11B1 (0.59) HSD11B1HSD11B2CES2CES1PTPN1
SCHEMBL420589 0.90 HSD11B1 (0.46) HSD11B1HSD11B2EGLN2EGLN1EGLN3
SCHEMBL421484 0.88 HSD11B1 (0.48) HSD11B1HSD11B2EGLN2EGLN1EGLN3
SCHEMBL13056308 0.86 CES2 (0.45) HSD11B1HSD11B2CES2CES1PTPN1
SCHEMBL418097 0.86 HSD11B1 (0.60) HSD11B1HSD11B2CES2CES1PTPN1
SCHEMBL419031 0.86 HSD11B1 (0.44) HSD11B1HSD11B2CES2CES1PTPN1
SCHEMBL1721886 0.85 PTPN1 (0.47) HSD11B1HSD11B2EGLN2EGLN1EGLN3
SCHEMBL422274 0.84 PTPN1 (0.57) HSD11B1HSD11B2EGLN2EGLN1EGLN3
SCHEMBL422227 0.83 CES2 (0.44) HSD11B1HSD11B2CES2CES1PTPN1
SCHEMBL421440 0.80 HSD11B1 (0.49) HSD11B1HSD11B2CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8476315-B2 N-hydroxy C29-amide derivatives of oleandrane ONEPHARM RESEARCH & DEVELOPMENT GMBH (AT) 2013-07-02 US disclosed
US-20120022154-A1 N-HYDROXY C29-AMIDE DERIVATIVES OF OLEANDRANE ONEPHARM RESEARCH & DEVELOPMENT GMBH (AT) 2012-01-26 US disclosed
EP-2228380-A1 Novel triterpene derivatives onepharm Research & Development GmbH (AT) 2010-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022154-A1 N-HYDROXY C29-AMIDE DERIVATIVES OF OLEANDRANE HSD11B1, CYP11B1, HSD11B2 HSD11B1 1/4885HSD11B2 3/4885EGLN2 707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.